Yongyuth Yuthavong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4111114/publications.pdf

Version: 2024-02-01

127 papers 4,481 citations

35 h-index 60 g-index

134 all docs

134 docs citations

134 times ranked

3658 citing authors

#	Article	IF	CITATIONS
1	Insights into antifolate resistance from malarial DHFR-TS structures. Nature Structural and Molecular Biology, 2003, 10, 357-365.	3.6	343
2	Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16823-16828.	3.3	237
3	Possible modes of action of the artemisinin-type compounds. Trends in Parasitology, 2001, 17, 122-126.	1.5	207
4	Inducible Knockdown of Plasmodium Gene Expression Using the glmS Ribozyme. PLoS ONE, 2013, 8, e73783.	1.1	202
5	The antimalarial action on Plasmodium falciparum of qinghaosu and artesunate in combination with agents which modulate oxidant stress. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1987, 81, 710-714.	0.7	162
6	An Overview of Chemotherapeutic Targets for Antimalarial Drug Discovery. , 1999, 81, 91-110.		131
7	Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with Plasmodium falciparum dihydrofolate reductase: structural basis of antifolate resistance. Bioorganic and Medicinal Chemistry, 2000, 8, 1117-1128.	1.4	128
8	Inhibitors of Multiple Mutants of Plasmodium falciparum Dihydrofolate Reductase and Their Antimalarial Activities. Journal of Medicinal Chemistry, 2004, 47, 673-680.	2.9	116
9	Correlation of Antimalarial Activity of Artemisinin Derivatives with Binding Affinity with Ferroprotoporphyrin IX. Journal of Medicinal Chemistry, 1997, 40, 633-638.	2.9	98
10	Development of 2,4-Diaminopyrimidines as Antimalarials Based on Inhibition of the S108N and C59R+S108N Mutants of Dihydrofolate Reductase from Pyrimethamine-Resistant Plasmodium falciparum. Journal of Medicinal Chemistry, 2002, 45, 1244-1252.	2.9	94
11	Crystal structure of dihydrofolate reductase from Plasmodium vivax: Pyrimethamine displacement linked with mutation-induced resistance. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13046-13051.	3.3	86
12	A Genetically Hard-Wired Metabolic Transcriptome in Plasmodium falciparum Fails to Mount Protective Responses to Lethal Antifolates. PLoS Pathogens, 2008, 4, e1000214.	2.1	83
13	Target Guided Synthesis of 5-Benzyl-2,4-diamonopyrimidines: Their Antimalarial Activities and Binding Affinities to Wild Type and Mutant Dihydrofolate Reductases fromPlasmodium falciparum. Journal of Medicinal Chemistry, 2004, 47, 345-354.	2.9	82
14	C-16 Artemisinin Derivatives and Their Antimalarial and Cytotoxic Activities:Â Syntheses of Artemisinin Monomers, Dimers, Trimers, and Tetramers by Nucleophilic Additions to Artemisitene. Journal of Medicinal Chemistry, 2001, 44, 4688-4695.	2.9	80
15	Basis for antifolate action and resistance in malaria. Microbes and Infection, 2002, 4, 175-182.	1.0	80
16	Rational Drug Design Approach for Overcoming Drug Resistance:Â Application to Pyrimethamine Resistance in Malaria. Journal of Medicinal Chemistry, 1998, 41, 1367-1370.	2.9	73
17	Heterologous expression of active thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum. Biochemistry, 1990, 29, 10779-10785.	1.2	71
18	Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Molecular and Biochemical Parasitology, 2002, 119, 63-73.	0.5	70

#	Article	IF	CITATIONS
19	De novo and salvage biosynthesis of pteroylpentaglutamates in the human malaria parasite, Plasmodium falciparum. Molecular and Biochemical Parasitology, 1989, 32, 25-37.	0.5	69
20	Mitochondria as the site of action of tetracycline on Plasmodium falciparum. Molecular and Biochemical Parasitology, 1989, 34, 109-115.	0.5	67
21	Anticancer Properties of Distinct Antimalarial Drug Classes. PLoS ONE, 2013, 8, e82962.	1.1	67
22	Development of a Lead Inhibitor for the A16V+S108T Mutant of Dihydrofolate Reductase from the Cycloguanil-Resistant Strain (T9/94) of Plasmodium falciparumâ€. Journal of Medicinal Chemistry, 2000, 43, 2738-2744.	2.9	64
23	Antimalarial Principles fromArtemisia indica. Journal of Natural Products, 1998, 61, 1146-1147.	1.5	56
24	Depression of Plasmodium falciparum dihydroorotate dehydrogenase activity in in vitro culture by tetracycline. Molecular and Biochemical Parasitology, 1988, 27, 119-124.	0.5	54
25	Exploiting Structural Analysis, <i>in Silico</i> Screening, and Serendipity To Identify Novel Inhibitors of Drug-Resistant Falciparum Malaria. ACS Chemical Biology, 2009, 4, 29-40.	1.6	54
26	Application of loop-mediated isothermal amplification assay combined with lateral flow dipstick for detection of Plasmodium falciparum and Plasmodium vivax. Parasitology International, 2014, 63, 777-784.	0.6	51
27	Plasmodium falciparum:Asparagine Mutant at Residue 108 of Dihydrofolate Reductase Is an Optimal Antifolate-Resistant Single Mutant. Experimental Parasitology, 1997, 87, 245-252.	0.5	49
28	Enhanced Ca2+ uptake by mouse erythrocytes in malarial (Plasmodium berghei) infection. Molecular and Biochemical Parasitology, 1983, 7, 227-235.	0.5	47
29	Characterization, crystallization and preliminary X-ray analysis of bifunctional dihydrofolate reductase–thymidylate synthase fromPlasmodium falciparum. Acta Crystallographica Section D: Biological Crystallography, 2004, 60, 780-783.	2.5	47
30	Inhibitors of Plasmodial Serine Hydroxymethyltransferase (SHMT): Cocrystal Structures of Pyrazolopyrans with Potent Blood- and Liver-Stage Activities. Journal of Medicinal Chemistry, 2015, 58, 3117-3130.	2.9	46
31	Synthesis of Solution-Phase Combinatorial Library of 4,6-Diamino-1,2-dihydro-1,3,5-triazine and Identification of New Leads Against A16V+S108T Mutant Dihydrofolate Reductase of Plasmodium falciparum. Bioorganic and Medicinal Chemistry, 2003, 11, 217-224.	1.4	45
32	Impaired Parasite Growth and Increased Susceptibility to Phagocytosis of <i>Plasmodium falciparum</i> Infected Alpha-Thalassemia or Hemoglobin Constant Spring Red Blood Cells. American Journal of Clinical Pathology, 1988, 89, 521-525.	0.4	44
33	Folate metabolism as a source of molecular targets for antimalarials. Future Microbiology, 2006, 1, 113-125.	1.0	44
34	Trypanosomal Dihydrofolate Reductase Reveals Natural Antifolate Resistance. ACS Chemical Biology, 2011, 6, 905-911.	1.6	42
35	Origin of Robustness in Generating Drug-Resistant Malaria Parasites. Molecular Biology and Evolution, 2014, 31, 1649-1660.	3.5	41
36	Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli. Molecular and Biochemical Parasitology, 2002, 120, 61-72.	0.5	40

#	Article	IF	CITATIONS
37	Characterization of Plasmodium falciparum serine hydroxymethyltransferase—A potential antimalarial target. Molecular and Biochemical Parasitology, 2009, 168, 63-73.	0.5	35
38	Mechanism-Based Development of New Antimalarials: Synthesis of Derivatives of Artemisinin Attached to Iron Chelators. Journal of Medicinal Chemistry, 1995, 38, 2311-2316.	2.9	33
39	Chemical synthesis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Molecular and Biochemical Parasitology, 1996, 83, 93-106.	0.5	32
40	Characterization of cobalamin-dependent methionine synthase purified from the human malarial parasite, Plasmodium falciparum. Zeitschrift Für Parasitenkunde (Berlin, Germany), 1989, 75, 512-517.	0.8	30
41	Molecular Dynamics of Interactions between Rigid and Flexible Antifolates and Dihydrofolate Reductase from Pyrimethamineâ€Sensitive and Pyrimethamineâ€Resistant <i>Plasmodium falciparum</i> . Chemical Biology and Drug Design, 2014, 84, 450-461.	1.5	30
42	Plasmodium parasites mount an arrest response to dihydroartemisinin, as revealed by whole transcriptome shotgun sequencing (RNA-seq) and microarray study. BMC Genomics, 2015, 16, 830.	1.2	29
43	Increased Phagocytosis of <i>Plasmodium falciparum</i> -Infected Erythrocytes with Haemoglobin E by Peripheral Blood Monocytes. Acta Haematologica, 1986, 76, 155-158.	0.7	28
44	Plasmodium serine hydroxymethyltransferase as a potential anti-malarial target: inhibition studies using improved methods for enzyme production and assay. Malaria Journal, 2012, 11, 194.	0.8	28
45	Combined Spatial Limitation around Residues 16 and 108 of Plasmodium falciparum Dihydrofolate Reductase Explains Resistance to Cycloguanil. Antimicrobial Agents and Chemotherapy, 2012, 56, 3928-3935.	1.4	27
46	Flow cytometric enumeration of Plasmodium berghei-infected red blood cells stained with SYBR Green I. Acta Tropica, 2012, 122, 113-118.	0.9	26
47	Biochemical and functional characterization of Plasmodium falciparum GTP cyclohydrolase I. Malaria Journal, 2014, 13, 150.	0.8	26
48	Stoichiometric Selection of Tight-Binding Inhibitors by Wild-Type and Mutant Forms of Malarial (Plasmodiumfalciparum) Dihydrofolate Reductase. Analytical Chemistry, 2005, 77, 1222-1227.	3.2	25
49	Preclinical Evaluation of the Antifolate QN254, 5-Chloro- <i>N</i> ′6′-(2,5-Dimethoxy-Benzyl)-Quinazoline-2,4,6-Triamine, as an Antimalarial Drug Candidate. Antimicrobial Agents and Chemotherapy, 2010, 54, 2603-2610.	1.4	25
50	The relationship of phosphorylation of membrane proteins with the osmotic fragility and filterability of Plasmodium berghei-infected mouse erythrocytes. Biochimica Et Biophysica Acta - Molecular Cell Research, 1987, 929, 278-287.	1.9	24
51	Subunit complementation of thymidylate synthase. Biochemistry, 1992, 31, 10303-10309.	1.2	24
52	Plasmodium serine hydroxymethyltransferase: indispensability and display of distinct localization. Malaria Journal, 2012, 11, 387.	0.8	24
53	Role of Plasmodium vivax Dihydropteroate Synthase Polymorphisms in Sulfa Drug Resistance. Antimicrobial Agents and Chemotherapy, 2016, 60, 4453-4463.	1.4	24
54	The structure of <i>PlasmodiumÂfalciparum</i> hydroxymethyldihydropterin pyrophosphokinaseâ€dihydropteroate synthase reveals the basis of sulfa resistance. FEBS Journal, 2020, 287, 3273-3297.	2.2	24

#	Article	IF	CITATIONS
55	Guanosine triphosphate cyclohydrolase in Plasmodium falciparum and other Plasmodium species. Molecular and Biochemical Parasitology, 1985, 17, 265-276.	0.5	23
56	Characterization of human malaria parasite Plasmodium falciparum elF4E homologue and mRNA 5′ cap status. Molecular and Biochemical Parasitology, 2007, 155, 146-155.	0.5	23
57	Structures of <i>Plasmodium vivax</i> serine hydroxymethyltransferase: implications for ligand-binding specificity and functional control. Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 3177-3186.	2.5	23
58	Identifying antimalarial compounds targeting dihydrofolate reductase-thymidylate synthase (DHFR-TS) by chemogenomic profiling. International Journal for Parasitology, 2016, 46, 527-535.	1.3	23
59	Binding of Dihydroartemisinin to Hemoglobin H: Role in Drug Accumulation and Host-Induced Antimalarial Ineffectiveness of α-Thalassemic Erythrocytes. Molecular Pharmacology, 1998, 53, 492-496.	1.0	22
60	Distinct biochemical properties of human serine hydroxymethyltransferase compared with the <i><scp>P</scp>lasmodium</i> enzyme: implications for selective inhibition. FEBS Journal, 2014, 281, 2570-2583.	2.2	22
61	The structure of <i>Plasmodium falciparum </i> serine hydroxymethyltransferase reveals a novel redox switch that regulates its activities. Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 1517-1527.	2.5	22
62	Conflicting Requirements of <i>Plasmodium falciparum</i> Dihydrofolate Reductase Mutations Conferring Resistance to Pyrimethamine-WR99210 Combination. Antimicrobial Agents and Chemotherapy, 2007, 51, 4356-4360.	1.4	21
63	Artemisinin effectiveness in erythrocytes is reduced by heme and heme-containing proteins. Biochemical Pharmacology, 2007, 74, 153-160.	2.0	21
64	Evidence for electrogenic accumulation of mefloquine by malarial parasites. Biochemical Pharmacology, 1988, 37, 3623-3631.	2.0	19
65	Evaluation of the Activities of Pyrimethamine Analogs against Plasmodium vivax and Plasmodium falciparum Dihydrofolate Reductase-Thymidylate Synthase Using In Vitro Enzyme Inhibition and Bacterial Complementation Assays. Antimicrobial Agents and Chemotherapy, 2006, 50, 3631-3637.	1.4	19
66	Serine hydroxymethyltransferase from <i>Plasmodiumâ€fvivax</i> is different in substrate specificity from its homologues. FEBS Journal, 2009, 276, 4023-4036.	2.2	19
67	Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance. ACS Medicinal Chemistry Letters, 2018, 9, 1235-1240.	1.3	19
68	Membrane heme as a host factor in reducing effectiveness of dihydroartemisinin. Biochemical Pharmacology, 2002, 64, 91-98.	2.0	17
69	Interactions between cycloguanil derivatives and wild type and resistance-associated mutant Plasmodium falciparum dihydrofolate reductases. Journal of Computer-Aided Molecular Design, 2009, 23, 241-252.	1.3	17
70	Effect of N-terminal truncation of Plasmodium falciparum dihydrofolate reductase on dihydrofolate reductase and thymidylate synthase activity. Molecular and Biochemical Parasitology, 2003, 126, 97-102.	0.5	16
71	Superoxide Dismutase (SOD) in Mouse Red Blood Cells Infected with Plasmodium berghei. Journal of Parasitology, 1982, 68, 337.	0.3	15
72	Mutational analysis of Plasmodium falciparum dihydrofolate reductase: the role of aspartate 54 and phenylalanine 223 on catalytic activity and antifolate binding. Molecular and Biochemical Parasitology, 2002, 121, 185-193.	0.5	15

#	Article	IF	CITATIONS
73	Alterations in membrane proteins of mouse erythrocytes infected with different species and strains of malaria parasites. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1979, 63, 83-85.	0.2	14
74	Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities. European Journal of Medicinal Chemistry, 2020, 195, 112263.	2.6	14
75	Inhibitory effect of $\hat{l}^2\hat{a}^{\sim}$ -thalassaemia/haemoglobin E erythrocytes on Plasmodium falciparum growth in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1987, 81, 903-906.	0.7	13
76	High-performance liquid chromatographic assay for thymidylate synthase from the human malaria parasite, plasmodium falciparum. Biomedical Applications, 1989, 487, 51-59.	1.7	13
77	Inactivation of artemisinin by thalassemic erythrocytes. Biochemical Pharmacology, 2000, 59, 1337-1344.	2.0	13
78	Particular interaction between pyrimethamine derivatives and quadruple mutant type dihydrofolate reductase of Plasmodium falciparum: CoMFA and quantum chemical calculations studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 471-479.	2.5	13
79	Cloning and heterologous expression of Plasmodium ovale dihydrofolate reductase-thymidylate synthase gene. Parasitology International, 2012, 61, 324-332.	0.6	13
80	Molecular characterization of Plasmodium falciparum Bruno/CELF RNA binding proteins. Molecular and Biochemical Parasitology, 2014, 198, 1-10.	0.5	12
81	Effect of inhibitors on glucose transport in malaria (Plasmodium berghei) infected erythrocytes. International Journal for Parasitology, 1986, 16, 441-446.	1.3	11
82	Bibliometric indicators of scientific activity in Thailand. Scientometrics, 1986, 9, 139-143.	1.6	11
83	Random Mutagenesis Strategies for Construction of Large and Diverse Clone Libraries of Mutated DNA Fragments., 2004, 270, 319-334.		11
84	Design, synthesis and biological evaluation of 6-aryl-1,6-dihydro-1,3,5-triazine-2,4-diamines as antiplasmodial antifolates. Organic and Biomolecular Chemistry, 2016, 14, 7899-7911.	1.5	11
85	High-performance liquid chromatographic determination of dihydroorotate dehydrogenase of Plasmodium falciparum and effects of antimalarials on enzyme activity. Biomedical Applications, 1992, 582, 57-64.	1.7	10
86	Kinetic Mechanism and the Rate-limiting Step of Plasmodium vivax Serine Hydroxymethyltransferase. Journal of Biological Chemistry, 2015, 290, 8656-8665.	1.6	10
87	Subunit complementation of thymidylate synthase in Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase. Molecular and Biochemical Parasitology, 2005, 139, 83-90.	0.5	9
88	The role of tryptophan-48 in catalysis and binding of inhibitors of Plasmodium falciparum dihydrofolate reductase. International Journal for Parasitology, 2007, 37, 787-793.	1.3	9
89	Relation between Low Erythrocyte Acetylcholinesterase Activity and Membrane Lipids in Paroxysmal Noctural Haemoglobinuria*. British Journal of Haematology, 1979, 41, 383-391.	1.2	8
90	Stimulation of Ca2+ uptake in the human liver fluke Opisthorchis viverrini by praziquantel. Life Sciences, 1983, 32, 2529-2534.	2.0	8

#	Article	IF	Citations
91	High-performance liquid chromatographic assay for pteroylpolyglutamate hydrolase. Biomedical Applications, 1987, 417, 47-56.	1.7	8
92	Crystallization and preliminary crystallographic studies of dihydrofolate reductase-thymidylate synthase from $\langle i \rangle$ Trypanosoma cruzi $\langle i \rangle$, the Chagas disease pathogen. Acta Crystallographica Section F: Structural Biology Communications, 2009, 65, 1175-1178.	0.7	8
93	Transgenic Plasmodium parasites stably expressing Plasmodium vivax dihydrofolate reductase-thymidylate synthase as in vitro and in vivo models for antifolate screening. Malaria Journal, 2011, 10, 291.	0.8	8
94	Estimating mRNA lengths from Plasmodium falciparum genes by Virtual Northern RNA-seq analysis. International Journal for Parasitology, 2016, 46, 7-12.	1.3	8
95	Transgenic pyrimethamine-resistant plasmodium falciparum reveals transmission-blocking potency of P218, a novel antifolate candidate drug. International Journal for Parasitology, 2021, 51, 635-642.	1.3	8
96	Distribution of chloroquine in normal, pronase-treated and malaria-infected red cells. Life Sciences, 1980, 26, 1899-1903.	2.0	7
97	Radical mechanism of action of the artemisinin-type compounds. Trends in Parasitology, 2001, 17, 267-268.	1.5	7
98	An Environmentally Friendly, Low Cost, One-Pot Synthesis of Artemisitene. Synthetic Communications, 2003, 33, 1855-1860.	1.1	7
99	Mechanisms of Antimalarial Drug Action and Resistance. , 2014, , 427-461.		7
100	6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum. Bioorganic and Medicinal Chemistry, 2019, 27, 115158.	1.4	7
101	Characteristics of Membrane Protein Phosphorylation in Plasmodium berghei-Infected Mouse Erythrocytes1. Journal of Protozoology, 1986, 33, 446-454.	0.9	6
102	Immobilization of Malarial (Plasmodium falciparum) Dihydrofolate Reductase for the Selection of Tight-Binding Inhibitors from Combinatorial Library. Analytical Chemistry, 2007, 79, 5006-5012.	3.2	6
103	Discovery of new non-pyrimidine scaffolds as <i>Plasmodium falciparum</i> DHFR inhibitors by fragment-based screening. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 198-206.	2.5	6
104	New Insights into Antimalarial Chemopreventive Activity of Antifolates. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0153821.	1.4	6
105	Rate constants of individual steps in papain-catalysed reactions. Biochimica Et Biophysica Acta - Biomembranes, 1978, 523, 198-206.	1.4	5
106	An Examination of Complement Proteins on Membranes of Paroxysmal Nocturnal Haemoglobinuria (PNH) and PNH-like Red Cells. British Journal of Haematology, 1979, 41, 393-398.	1.2	5
107	Cloning and characterization of Plasmodium vivax serine hydroxymethyltransferase. Parasitology International, 2008, 57, 223-228.	0.6	5
108	Formation of catalytically active cross-species heterodimers of thymidylate synthase from Plasmodium falciparum and Plasmodium vivax. Molecular Biology Reports, 2011, 38, 1029-1037.	1.0	5

#	Article	IF	Citations
109	Selection of drug resistant mutants from random library of Plasmodium falciparum dihydrofolate reductase in Plasmodium berghei model. Malaria Journal, 2011, 10, 119.	0.8	5
110	Cytochrome c and c1 heme lyases are essential in Plasmodium berghei. Molecular and Biochemical Parasitology, 2016, 210, 32-36.	0.5	5
111	Characterization of Plasmodium knowlesi dihydrofolate reductase-thymidylate synthase and sensitivity to antifolates. Parasitology International, 2018, 67, 787-792.	0.6	5
112	Crystal structure of Plasmodium falciparum adenosine deaminase reveals a novel binding pocket for inosine. Archives of Biochemistry and Biophysics, 2019, 667, 6-13.	1.4	4
113	Effect of membrane modification on cell fusion of hen erythrocytes induced by dimethyl sulfoxide. Life Sciences, 1978, 22, 1993-1997.	2.0	3
114	Antifolate Drugs., 2013,, 1-12.		3
115	Structural Insight into Effective Inhibitors' Binding to <i>Toxoplasma gondii</i> Dihydrofolate Reductase Thymidylate Synthase. ACS Chemical Biology, 2022, 17, 1691-1702.	1.6	3
116	Science and technology in Southeast Asia. Nature, 1978, 274, 634-636.	13.7	2
117	Use of bacterial surrogates as a tool to explore antimalarial drug interaction: Synergism between inhibitors of malarial dihydrofolate reductase and dihydropteroate synthase. Acta Tropica, 2015, 149, 64-69.	0.9	2
118	Different states of sarcoplasmic reticulum membrane in the presence of acetyl phosphate and adenosine triphosphate. Life Sciences, 1977, 21, 713-718.	2.0	1
119	Current Biotechnological Developments in Thailand. Critical Reviews in Biotechnology, 1989, 9, 41-59.	5.1	1
120	Small-scale in vitro culture and purification of Plasmodium berghei for transfection experiment. Molecular and Biochemical Parasitology, 2011, 177, 156-159.	0.5	1
121	Title is missing!. ScienceAsia, 1996, 22, 181.	0.2	1
122	Active partnership of Third World scientists. Nature, 1979, 280, 529-530.	13.7	0
123	Sparks from the Spirit., 0, , .		0
124	Interaction of Education with Research and Development. Education in the Asia-Pacific Region, 2018, , 411-421.	0.2	0
125	ScienceAsia, Journal of the Science Society of Thailand, reflects maturation of science in Thailand. ScienceAsia, 2018, 44S, 1.	0.2	0
126	Assay Development and Identification of the First Plasmodium falciparum 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase Inhibitors. Molecules, 2022, 27, 3515.	1.7	0

#	Article	IF	CITATIONS
127	Key interactions of pyrimethamine derivatives specific to wild-type and mutant <i>P. falciparum</i> dihydrofolate reductase based on 3D-QSAR, MD simulations and quantum chemical calculations. Journal of Biomolecular Structure and Dynamics, 2023, 41, 5728-5743.	2.0	0